Drug Class:
Bisphosphonates

PharmGKB contains no dosing guidelines for this drug class. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug class. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs11064477 *333+150C>T, 166785G>A, 7014365G>A, 7074365G>A
G > A
Intronic
No VIP available CA VA
rs11189381 50367662T>C, 99563198T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs11264359 -34+643A>G, 155282829A>G, 282+643A>G, 480+643A>G, 6771471A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs11934877 40526A>G, 476-33927A>G, 5280909T>C, 57941026T>C
T > C
Intronic
No VIP available CA VA
rs12903202 -663T>C, 118-314T>C, 29097350A>G, 55-314T>C, 56114T>C, 58306793A>G
A > G
Intronic
No VIP available CA No Variant Annotations available
rs1544410 1024+283G>A, 10383141C>T, 1174+283G>A, 48239835C>T, 63980G>A, VDR: BsmI, VDR:BsmI
C > T
Intronic
No VIP available CA VA
rs1678387 3211-2793A>G, 8807582T>C, 95717906T>C
T > C
Intronic
No VIP available CA VA
rs16944 -598T>C, 113594867A>G, 3343530A>G, 4490T>C, IL1B: -511 C/T
A > G
5' Flanking
No VIP available CA VA
rs17024608 29894690A>G, 29954690A>G, 885+15724A>G, 939+13444A>G, 978+13444A>G
A > G
Intronic
No VIP available CA VA
rs17751934 152281G>A, 30690916C>T, 49201814C>T
G > T
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs1886629 196154898C>T, 47643540C>T
C > T
Not Available
No VIP available No Clinical Annotations available VA
rs193451 108310986A>G, 46343829A>G
A > G
Not Available
No VIP available CA VA
rs1934951 1081+106G>A, 1291+106G>A, 35707G>A, 47603012C>T, 96798548C>T, 985+106G>A
C > T
Intronic
No VIP available CA VA
rs2297480 -1-373T>G, -1-98T>G, -175+726T>G, -22-352T>G, 155279482T>G, 6768124T>G
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs4431170 -114+19765T>C, 165284574A>G, 89832295A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs5768434 27989421C>T, 48598852C>T
C > T
Not Available
No VIP available CA VA
rs7588295 -24+33040A>G, 16616929A>G, 166407511A>G
A > G
Intronic
No VIP available CA VA
rs7740004 120856203T>A, 25025660T>A
T > A
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Generic Names
  • Bisphosphonate
Trade Names
Brand Mixture Names

PharmGKB Accession Id:
PA164712563

Other Vocabularies

Drugs And Small Molecules

The following have been classified under this therapeutic category:

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to Bisphosphonates: 17

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenetics and genomics. 2013. Aquilante Christina L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The future of pharmacogenetics for osteoporosis. Pharmacogenomics. 2013. Marini Francesca, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. The oncologist. 2012. Nicoletti Paola, et al. PubMed
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica. 2011. Such Esperanza, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International journal of oral and maxillofacial surgery. 2011. Katz J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Frontiers in bioscience (Elite edition). 2011. Marini Francesca, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates. The pharmacogenomics journal. 2010. Olmos J M, et al. PubMed
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management. 2010. English Bevin C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. Calcified tissue international. 2008. Mossetti Giuseppe, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Annals of hematology. 2008. Otrock Zaher K, et al. PubMed
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008. Sarasquete Maria E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Current medical research and opinion. 2008. Marini Francesca, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
-511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Bone. 2006. Corral-Gudino Luis, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2005. Palomba Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clinical endocrinology. 2003. Palomba Stefano, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2002. Tofteng C L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1999. Marc J, et al. PubMed

Clinical Trials

These are trials that mention Bisphosphonates and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.